<DOC>
	<DOCNO>NCT01360632</DOCNO>
	<brief_summary>To compare effect OPC-34712 ( brexpiprazole ) effect placebo ( inactive substance ) add treatment assigned FDA approve antidepressant treatment ( ADT ) patient Major Depressive Disorder demonstrate incomplete response prospective trial assign FDA approve ADT</brief_summary>
	<brief_title>Study Safety Efficacy Two Fixed Doses OPC-34712 Adjunctive Therapy Treatment Adults With Major Depressive Disorder ( Polaris Trial )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Male female subject 18 65 year age , diagnosis major depressive disorder , define DSMIVTR criteria The current depressive episode must equal great 8 week duration Subjects must report history current depressive episode inadequate response three adequate antidepressant treatment Females breastfeed and/or positive pregnancy test result prior receive study drug Subjects report inadequate response three adequate trial antidepressant treatment current depressive episode therapeutic dose adequate duration Subjects current Axis I ( DSMIVTR ) diagnosis : Delirium , dementia , amnestic cognitive disorder , Schizophrenia , schizoaffective disorder , psychotic disorder , Bipolar I II disorder Subjects clinically significant current Axis II ( DSMIVTR ) diagnosis borderline , antisocial , paranoid , schizoid , schizotypal histrionic personality disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>OPC-34712</keyword>
	<keyword>brexpiprazole</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Adjunctive Treatment</keyword>
</DOC>